Strides Arcolab gets USFDA approval for Bangalore facility

NEW DELHI: Drug firm Strides Arcolab's manufacturing facility in Bangalore has been approved by the US health regulator after a successful audit of the plant, the company said today.

"Oral Dosage Forms manufacturing site (KRS Gardens) in Bangalore was recently inspected by the US Food and Drug Administration ( USFDA) as part of GMP compliance audit and the facility continues to be approved," Strides Arcolab said in a statement.

The last USFDA inspection and approval for this facility was in the year 2011, it added.

The KRS Gardens facility in Bangalore manufactures oral dosage forms such as tablets, capsules (both hard gelatine and soft gelatine) and sachets.

The manufacturing plant supports important current and future submissions for the US market, the company said.

Strides Arcolab shares were trading at Rs 505.35 apiece on the BSE in late afternoon trade, up 8.44 per cent from its previous close.